# Chugai Pharmaceutical

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/chugai-pharmaceutical/

## Facts

| Field | Value |
| --- | --- |
| Country | JP |
| Description | Switzerland company in Japan |
| OpenAlex ID | https://openalex.org/F4320333003 |
| ROR ID | https://ror.org/01vepzj85 |
| Works | 8,495 |

## Funder papers

- [Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases](https://scholariq.org/papers/executive-summary-of-the-kdigo-2021-guideline-for-the-management-of-glomerular/)
- [Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy](https://scholariq.org/papers/small-cell-transformation-in-egfr-mutated-non-small-cell-lung-cancer-dll3/)
- [Genetic background, recent advances in molecular biology, and development of novel therapy in Alport syndrome](https://scholariq.org/papers/genetic-background-recent-advances-in-molecular-biology-and-development-of-novel/)
- [Hemolysis induced by SARS-CoV-2 mRNA vaccination in patients with paroxysmal nocturnal hemoglobinuria](https://scholariq.org/papers/hemolysis-induced-by-sars-cov-2-mrna-vaccination-in-patients-with-paroxysmal/)
- [Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial](https://scholariq.org/papers/simultaneous-initiation-of-finerenone-and-empagliflozin-across-the-spectrum-of/)
- [What do clinical trials teach us about the pathophysiology of human IgA nephropathy?](https://scholariq.org/papers/what-do-clinical-trials-teach-us-about-the-pathophysiology-of-human-iga/)
- [ARAF Amplification in Small-Cell Lung Cancer-Transformed Tumors Following Resistance to Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors](https://scholariq.org/papers/araf-amplification-in-small-cell-lung-cancer-transformed-tumors-following/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.